517 lines
No EOL
105 KiB
HTML
517 lines
No EOL
105 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548591" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548591/" /><meta name="ncbi_pagename" content="Protein Kinase Inhibitors - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Protein Kinase Inhibitors - LiverTox - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Protein Kinase Inhibitors" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2024/11/13" /><meta name="citation_pmid" content="31643906" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548591/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Protein Kinase Inhibitors" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2024/11/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548591/" /><meta name="description" content="The kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target protein kinases that are altered in cancer cells and that account for some of their abnormal growth. Protein kinases are ubiquitous intracellular and cell surface proteins that play critical roles in cell signaling pathways involved in metabolism, injury responses, adaption, growth and differentiation. They act by adding a phosphate group to a protein (phosphorylation), usually on a specific amino acid which often makes the protein or enzyme "active". The human genome has more than 500 protein kinases and they can be classified as (1) tyrosine, (2) serine-theonine or (3) nonspecific (both), based upon their amino acid specificity. Many protein kinases are cell surface receptors and act to initiate an intracellular pathway of activation, after the receptor is engaged by its ligand, typically a cytokine or growth factor. Inhibitors of these kinases are called protein kinase receptor inhibitors. Other kinases are intracellular and take part in cell signaling. These kinases can be targeted by "non-receptor" protein kinases. Finally, some kinase inhibitors have specificity for multiple kinases and are called "multi-kinase inhibitors."" /><meta name="og:title" content="Protein Kinase Inhibitors" /><meta name="og:type" content="book" /><meta name="og:description" content="The kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target protein kinases that are altered in cancer cells and that account for some of their abnormal growth. Protein kinases are ubiquitous intracellular and cell surface proteins that play critical roles in cell signaling pathways involved in metabolism, injury responses, adaption, growth and differentiation. They act by adding a phosphate group to a protein (phosphorylation), usually on a specific amino acid which often makes the protein or enzyme "active". The human genome has more than 500 protein kinases and they can be classified as (1) tyrosine, (2) serine-theonine or (3) nonspecific (both), based upon their amino acid specificity. Many protein kinases are cell surface receptors and act to initiate an intracellular pathway of activation, after the receptor is engaged by its ligand, typically a cytokine or growth factor. Inhibitors of these kinases are called protein kinase receptor inhibitors. Other kinases are intracellular and take part in cell signaling. These kinases can be targeted by "non-receptor" protein kinases. Finally, some kinase inhibitors have specificity for multiple kinases and are called "multi-kinase inhibitors."" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548591/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/ProteinKinaseInhibit/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548591/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8E272D7C8D85F10000000000CD00B3.m_13" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
<div id="universal_header">
|
|
<section class="usa-banner">
|
|
<div class="usa-accordion">
|
|
<header class="usa-banner-header">
|
|
<div class="usa-grid usa-banner-inner">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
|
<p>An official website of the United States government</p>
|
|
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
|
<span class="usa-banner-button-text">Here's how you know</span>
|
|
</button>
|
|
</div>
|
|
</header>
|
|
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
|
<div class="usa-banner-guidance-gov usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The .gov means it's official.</strong>
|
|
<br />
|
|
Federal government websites often end in .gov or .mil. Before
|
|
sharing sensitive information, make sure you're on a federal
|
|
government site.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The site is secure.</strong>
|
|
<br />
|
|
The <strong>https://</strong> ensures that you are connecting to the
|
|
official website and that any information you provide is encrypted
|
|
and transmitted securely.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<div class="usa-overlay"></div>
|
|
<header class="ncbi-header" role="banner" data-section="Header">
|
|
|
|
<div class="usa-grid">
|
|
<div class="usa-width-one-whole">
|
|
|
|
<div class="ncbi-header__logo">
|
|
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ncbi-header__account">
|
|
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
|
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
|
<span class="fa fa-user" aria-hidden="true">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
|
<g style="fill: #fff">
|
|
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
|
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
|
</g>
|
|
</svg>
|
|
</span>
|
|
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
|
<span class="sr-only">Show account info</span>
|
|
</button>
|
|
</div>
|
|
|
|
<div class="ncbi-popup-anchor">
|
|
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
|
<div class="ncbi-popup-head">
|
|
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
|
<span class="fa fa-times">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
|
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
|
</svg>
|
|
</span>
|
|
<span class="usa-sr-only">Close</span></button>
|
|
<h4>Account</h4>
|
|
</div>
|
|
<div class="account-user-info">
|
|
Logged in as:<br />
|
|
<b><span class="username" id="uname_long">username</span></b>
|
|
</div>
|
|
<div class="account-links">
|
|
<ul class="usa-unstyled-list">
|
|
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
|
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
|
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
|
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</div>
|
|
</header>
|
|
<div role="navigation" aria-label="access keys">
|
|
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
|
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
|
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
|
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
|
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
|
</div>
|
|
<section data-section="Alerts">
|
|
<div class="ncbi-alerts-placeholder"></div>
|
|
</section>
|
|
</div>
|
|
<div class="header">
|
|
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
|
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="pubmed">PubMed</option><option value="clinvar">ClinVar</option><option value="gquery" class="last">All Databases</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
|
<a href="/books/browse/">Browse Titles</a>
|
|
</li><li>
|
|
<a href="/books/advanced/">Advanced</a>
|
|
</li><li class="help">
|
|
<a href="/books/NBK3833/">Help</a>
|
|
</li><li class="disclaimer">
|
|
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
|
</li></ul></div>
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<!-- Custom content 1 -->
|
|
<div class="col1">
|
|
|
|
</div>
|
|
|
|
<div class="container">
|
|
<div id="maincontent" class="content eight_col col">
|
|
<!-- Custom content in the left column above book nav -->
|
|
<div class="col2">
|
|
|
|
</div>
|
|
|
|
<!-- Book content -->
|
|
|
|
|
|
<!-- Custom content between navigation and content -->
|
|
<div class="col3">
|
|
|
|
</div>
|
|
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548591_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548591_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/HIVProteaseInhibitor/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/ProtonPumpInhibitors/" title="Next page in this title">Next ></a></div></div></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548591_"><span class="title" itemprop="name">Protein Kinase Inhibitors</span></h1><p class="small">Last Update: <span itemprop="dateModified">November 13, 2024</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="ProteinKinaseInhibit.OVERVIEW"><h2 id="_ProteinKinaseInhibit_OVERVIEW_">OVERVIEW</h2><p>The kinase inhibitors are a large group of unique and potent antineoplastic agents which specifically target protein kinases that are altered in cancer cells and that account for some of their abnormal growth. Protein kinases are ubiquitous intracellular and cell surface proteins that play critical roles in cell signaling pathways involved in metabolism, injury responses, adaption, growth and differentiation. They act by adding a phosphate group to a protein (phosphorylation), usually on a specific amino acid which often makes the protein or enzyme "active". The human genome has more than 500 protein kinases and they can be classified as (1) tyrosine, (2) serine-theonine or (3) nonspecific (both), based upon their amino acid specificity. Many protein kinases are cell surface receptors and act to initiate an intracellular pathway of activation, after the receptor is engaged by its ligand, typically a cytokine or growth factor. Inhibitors of these kinases are called protein kinase receptor inhibitors. Other kinases are intracellular and take part in cell signaling. These kinases can be targeted by "non-receptor" protein kinases. Finally, some kinase inhibitors have specificity for multiple kinases and are called "multi-kinase inhibitors."</p><p>Protein kinases can be specifically involved in cell growth, proliferation and differentiation and mutations may lead to unregulated growth and proliferation that is typical of cancerous cells. These mutated protein kinases represent an attractive target for anticancer agents. The potent activity and lack of generalized toxicity of the kinase inhibitors relate to the specificity of antagonist for the mutated protein. In like manner, their toxicity often relates to off-target activity, either to the unmutated kinase or to closely related, normal kinases.</p><p>The protein kinases can be categorized based upon the amino acid that they phosphorylate: either serine, threonine or tyrosine. The tyrosine kinase receptor inhibitors were the initial and are perhaps the best characterized kinase inhibitors. The protein kinase inhibitors are relatively recently developed agents, all having been introduced since 2001. They are unique and represent a major advance in cancer chemotherapy, away from broadly cytotoxic agents and towards drugs that specifically target the molecular abnormalities of cancer cells. The initial tyrosine kinase inhibitor approved for use in the United States was imatinib (Gleevec: 2001) which is used to treat Philadelphia chromosome positive chronic lymphocytic leukemia, which has a mutated kinase receptor (BCR-ABL) that is created by the specific translocation that creates the Philadelphia chromosome. Imatinib is a specific inhibitor of the BCR-ABL kinase. The introduction of this first protein kinase inhibitor was followed by more than a dozen others within the next 10 years.</p><p>While most kinase inhibitors are antineoplastic agents, a few are also used for benign conditions including macular degeneration (pegaptanib), rheumatoid arthritis (tofacitinib) and idiopathic pulmonary fibrosis (nintedanib). Generally, however, the side effect profile of kinase inhibitors are such that they are reserved for severe, progressive, debilitating or potentially fatal conditions.</p><p>The protein kinase inhibitors all have some degree of hepatotoxicity and many have been linked to cases of clinically apparent liver injury which can be severe and even fatal. Interestingly, some of the cases of liver injury attributed to the protein kinase antagonists had features of autoimmunity, so that the liver injury may be caused by an immunologic reaction to metabolic products of the agent itself, rather than off-target activity of the inhibitor. In addition, at least two protein kinase inhibitors (imatinib and nilotinib) have been linked to instances of reactivation of hepatitis B. It is not clear whether this relates to a specific activity of the kinase inhibitor on hepatitis B virus replication or whether it is due to immunosuppression. Other kinase inhibitors have been linked to cases of rare and idiosyncratic liver injury, which can be hepatocellular or cholestatic and is typically self-limited but may be fatal.</p><p>The Table below lists the protein kinase inhibitors discussed in LiverTox, their brand name, predominant protein kinase (PK) specificity, year of approval in the United States, likelihood score, and major clinical uses.</p><div id="ProteinKinaseInhibit.PROTEIN_KINASE_INHI"><h3>
|
|
<u>PROTEIN KINASE INHIBITORS</u>
|
|
</h3><p>
|
|
<i>Underlined Generic Names link to a LiverTox record.</i>
|
|
</p><div id="ProteinKinaseInhibit.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548591/table/ProteinKinaseInhibit.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ProteinKinaseInhibit.Tc_lrgtbl__"><table><tbody><tr><td colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>CANCER</b>
|
|
</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Generic Name</b>
|
|
<br />
|
|
<b>Brand Name</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Kinase Target</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Approval</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Likelihood<br />Score†</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Major Uses††</b>
|
|
</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Abemaciclib/">Abemaciclib</a><br />Verzenio</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cyclin dependent kinase 4/6</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Acalabrutinib/">Acalabrutinib</a><br />Calquence</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bruton kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mantel cell lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Adagrasib/">Adagrasib</a><br />Krazati</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KRAS</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2022</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Afatinib/">Afatinib</a><br />Gilotrif</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGFR, HER2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2013</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Alectinib/">Alectinib</a><br />Alecensa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Alpelisib/">Alpelisib</a><br />Piqray</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PIK3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer, HR positive, HER2 negative</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Asciminib/">Asciminib</a><br />Scemblix</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ABL1 Myristoyl</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Avapritinib/">Avapritinib</a><br />Ayvakit</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PDGFRA, KIT</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gastrointestinal stromal tumors</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Axitinib/">Axitinib</a><br />Inlyta</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 1-3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Renal cell cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/EncorafenibBinimetin/">Binimetinib</a><br />Mektovi</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRAF</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Bortezomib/">Bortezomib</a><br />Velcade</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proteasome</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2003</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multiple myeloma, Mantle cell lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Bosutinib/">Bosutinib</a><br />Bosulif</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BCR-ABL, scr</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML, resistant</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Brigatinib/">Brigatinib</a><br />Alunbrig</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Cabozantinib/">Cabozantinib</a><br />Cometriq, Cabometyx</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MET, VEGFR-2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medullary thyroid cancer, Renal cell cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Capmatinib/">Capmatinib</a><br />Tabrecta</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MET</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Carfilzomib/">Carfilzomib</a><br />Kyprolis</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proteasome</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multiple myeloma, resistant</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ceritinib/">Ceritinib</a><br />Zykadia</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Cobimetinib/">Cobimetinib</a><br />Cotellic</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MEK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Copanlisib/">Copanlisib</a><br />Aliqopa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PI3Kα/δ</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Follicular lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Crizotinib/">Crizotinib</a><br />Xalkori</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2011</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Dabrafenib/">Dabrafenib</a><br />Tafinlar</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRAF</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2013</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Dacomitinib/">Dacomitinib</a><br />Vizimpro</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HER1,2,3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Dasatinib/">Dasatinib</a><br />Sprycel</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BCR-ABL, src</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2006</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML, resistant</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Duvelisib/">Duvelisib</a><br />Copiktra</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PI3K</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CLL, Small cell lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Enasidenib/">Enasidenib</a><br />IDHIFA</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mutant IDH-2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/EncorafenibBinimetin/">Encorafenib</a><br />Braftovi</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRAF</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Entrectinib/">Entrectinib</a><br />Rozlytrek</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NTRK, ROS1</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Erdafitinib/">Erdafitinib</a><br />Balversa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Urothelial cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Erlotinib/">Erlotinib</a><br />Tarceva</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGFR, HER1</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2004</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC, Pancreatic cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Fedratinib/">Fedratinib</a><br />Inrebic</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">JAK-2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myelofibrosis</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Futibatinib/">Futibatinib</a>
|
|
<br />Lytgobi</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2022</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholangiocarcinoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Gefitinib/">Gefitinib</a><br />Iressa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2009</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Gilteritinib/">Gilteritinib</a><br />Xospata</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FLT3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Glasdegib/">Glasdegib</a><br />Daurismo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hedgehog</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ibrutinib/">Ibrutinib</a><br />Imbruvica</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bruton kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2013</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mantle cell lymphoma, CLL</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Idelalisib/">Idelalisib</a><br />Zydelig</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PI3Kδ</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CLL, Non-Hodgkin lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Imatinib/">Imatinib</a><br />Gleevec</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BCR-ABL, c-Kit</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2001</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML, GIST</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Infigratinib/">Infigratinib</a>
|
|
<br />Truseltiq</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholangiocarcinoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ivosidenib/">Ivosidenib</a><br />Tibsovo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mutant IDH-1</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ixazomib/">Ixazomib</a><br />Ninlaro</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26S Proteasome</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multiple myeloma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Lapatinib/">Lapatinib</a><br />Tykerb</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGFR, HER2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2007</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer, HER2 positive</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Larotrectinib/">Larotrectinib</a><br />Vitrakvi</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NTRK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Solid tumors</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Lenvatinib/">Lenvatinib</a><br />Lenvima</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 1-3, FGF 1-4, PDGF, c-Kit, RET</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015<br />2016<br />2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Thyroid cancer<br />Renal cell cancer<br />Hepatocellular cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Lorlatinib/">Lorlatinib</a><br />Lorbrena</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Midostaurin/">Midostaurin</a><br />Rydapt</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FLT3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Mobocertinib/">Mobocertinib</a><br />Exkivity</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGFR exon 20</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Momelotinib/">Momelotinib</a><br />Ojjaara</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">JAK-1/2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myelofibrosis</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Neratinib/">Neratinib</a><br />Nerlynx</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HER2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Nilotinib/">Nilotinib</a><br />Tasigna</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BCR-ABL</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2007</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML, resistant</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Niraparib/">Niraparib</a><br />Zejula</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARP</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ovarian cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Olaparib/">Olaparib</a><br />Lynparza</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARP</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014<br />2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ovarian cancer<br />Advanced breast cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Olutasidenib/">Olutasidenib</a><br />Rezlidhia</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mutant IDH-1</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2022</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Osimertinib/">Osimertinib</a><br />Tagrisso</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC, refractory</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Pacritinib/">Pacritinib</a><br />Vonjo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">JAK2, FLT3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myelofibrosis</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Palbociclib/">Palbociclib</a><br />Ibrance</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ER+, HER2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer, HER2 negative</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Pazopanib/">Pazopanib</a><br />Votrient</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 1-3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2009</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Renal cell cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Pemigatinib/">Pemigatinib</a>
|
|
<br />Pemazyre</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholangiocarcinoma<br />Myeloid or lymphoid neoplasms</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Pexidartinib/">Pexidartinib</a><br />Turalio</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CSF1, FLT3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tenosynovial giant cell tumor</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Pirtobrutinib/">Pirtobrutinib</a><br />Jaypirca</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bruton kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mantel cell lymphoma<br />CLL, Small cell lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ponatinib/">Ponatinib</a><br />Iclusig</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BCR-ABL</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2013</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML, ALL</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Pralsetinib/">Pralsetinib</a><br />Gavreto</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RET</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020 –<br />Accel.<br /><p>2023</p></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC, Thyroid cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Quizartinib/">Quizartinib</a><br />Vanflyta</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FLT3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AML</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Regorafenib/">Regorafenib</a><br />Stivarga</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 1-3, PDGF</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Colorectal cancer, GIST</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ribociclib/">Ribociclib</a><br />Kisqali</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cyclin dependent kinase 4/6</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ripretinib/">Ripretinib</a><br />Qinlock</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PDGFRA, KIT</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gastrointestinal stromal tumors</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Rucaparib/">Rucaparib</a><br />Rubraca</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARP</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2016</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ovarian cancer, advanced</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ruxolitinib/">Ruxolitinib</a><br />Jakafi</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">JAK-1/2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2011<br /><p>2014</p>
|
|
<p>2019</p></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myelofibrosis<br /><p>Polycythemia vera</p>
|
|
<p>Acute graft-vs-host disease, steroid-resistant</p></td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Selpercatinib/">Selpercatinib</a><br />Retevmo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RET</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020 –<br />2022</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC, Thyroid Cancer<br />[2020 Accel., 2022 NSCLC Approval]<br /><p>Solid Tumors</p>
|
|
<p>[2022 Accel.]</p></td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Selumetinib/">Selumetinib</a><br />Koselugo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MEK 1/2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Neurofibromatosis type 1</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Sonidegib/">Sonidegib</a><br />Odomzo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hedgehog</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2015</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Basal cell skin cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Sorafenib/">Sorafenib</a><br />Nexavar</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 1-3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2005<br />2007<br />2013</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Renal cell cancer<br />Hepatocellular cancer<br />Thyroid cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><br /><a href="/books/n/livertox/Sotorasib/">Sotorasib</a><br />Lumakras</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">KRAS</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><br /><a href="/books/n/livertox/Sunitinib/">Sunitinib</a><br />Sutent</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PDGF, c-Kit</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2006</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">B</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CML, resistant; GIST, renal cell cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Talazoparib/">Talazoparib</a><br />Talzenna</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARP</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Tepotinib/">Tepotinib</a><br />Tepmetko</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MET</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Tivozanib/">Tivozanib</a><br />Fotivda</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR-1,2,3, c-kit,<br />PDGFR-β</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Renal cell cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Trametinib/">Trametinib</a><br />Mekinist</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MEK 1/2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2013</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Trilaciclib/">Trilaciblib</a><br />Cosela</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cyclin dependent kinase 4/6</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prevention of chemotherapy-induced myelosuppression in SCLC</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Tucatinib/">Tucatinib</a><br />Tukysa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HER2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020<br />2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Breast cancer<br />Colorectal cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Umbralisib/">Umbralisib</a><br />Ukoniq</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PI3Kδ</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Follicular lymphoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Vandetanib/">Vandetanib</a><br />Caprelsa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2011</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medullary thyroid cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Vemurafenib/">Vemurafenib</a><br />Zelboraf</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRAF</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2011</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Melanoma</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Vismodegib/">Vismodegib</a><br />Erivedge</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hedgehog</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Basal cell skin cancer</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Zanubrutinib/">Zanubrutinib</a><br />Brukinsa</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BTK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mantel cell lymphoma</td></tr><tr><td colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>MISCELLANEOUS</b>
|
|
</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Generic Name</b>
|
|
<br />
|
|
<b>Brand Name</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Kinase Target</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Approval</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Likelihood<br />Score†</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Major Uses††</b>
|
|
</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Abrocitinib/">Abrocitinib</a><br />Cibinqo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Janus kinase 1</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2022</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Atopic dermatitis</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Baricitinib/">Baricitinib</a><br />Olumiant</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Janus kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2018<br /><p>2022</p></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rheumatoid arthritis<br /><p>Alopecia areata</p></td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Belumosudil/">Belumosudil</a><br />Rezurock</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ROCK</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2021</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Graft-versus-host disease</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Deucravacitinib/">Deucravacitinib</a><br />Sotyktu</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tyrosine kinase 2</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plaque psoriasis</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Deuruxolitinib/">Deuruxolitinib</a><br />Leqselvi</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Janus kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2024</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alopecia areata</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Fostamatinib/">Fostamatinib</a><br />Tavalisse</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spleen tyrosine kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2017</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Immune thrombocytopenia</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Leniolisib/">Leniolisib</a><br />Joenja</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PI3Kδ</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Activated PI3K-delta Syndrome</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Lonafarnib/">Lonafarnib</a><br />Zokinvy</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FTase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2020</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Progeria syndrome</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Nintedanib/">Nintedanib</a><br />Ofev</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR, FGFR, PDGFR</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2014</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pulmonary fibrosis</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/MacularDegenerAgents/">Pegaptanib</a><br />Macugen</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VEGFR 1-3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2004</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Macular degeneration</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Ritlecitinib/">Ritlecitinib</a><br />Litfulo</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Janus kinase 3</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2023</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alopecia areata</td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Tofacitinib/">Tofacitinib</a><br />Xeljanz</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Janus kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2012<br /><p>2017</p>
|
|
<p>2018</p></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">E*</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rheumatoid arthritis<br /><p>Psoriatic arthritis</p>
|
|
<p>Ulcerative colitis</p></td></tr><tr><td scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="/books/n/livertox/Upadacitinib/">Upadacitinib</a><br />Rinvoq</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Janus kinase</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2019</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">D</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rheumatoid arthritis</td></tr></tbody></table></div></div><p><b>†</b> Likelihood Score indicates the likelihood of association with drug induced liver injury, based upon the known potential of the drug to cause such injury.</p><p><b>††</b> Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; GIST, gastrointestinal stromal tumor; NSCLC, non-small cell lung cancer.</p></div></div><div id="bk_toc_contnr"></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548591</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31643906" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31643906</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/HIVProteaseInhibitor/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/ProtonPumpInhibitors/" title="Next page in this title">Next ></a></div></div></div></div>
|
|
|
|
</div>
|
|
|
|
<!-- Custom content below content -->
|
|
<div class="col4">
|
|
|
|
</div>
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<!-- Custom contetnt below bottom nav -->
|
|
<div class="col5">
|
|
|
|
</div>
|
|
</div>
|
|
|
|
<div id="rightcolumn" class="four_col col last">
|
|
<!-- Custom content above discovery portlets -->
|
|
<div class="col6">
|
|
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548591&db=books">Share</a></div>
|
|
|
|
</div>
|
|
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548591/?report=reader">PubReader</a></li><li><a href="/books/NBK548591/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548591" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548591" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Protein Kinase Inhibitors. [Updated 2024 Nov 13].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548591/pdf/Bookshelf_NBK548591.pdf">PDF version of this page</a> (144K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>New and Updated</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22LiverTox%22+AND+pmcbook&sort=date&size=200" ref="pagearea=source-links&targetsite=external&targetcat=link&targettype=uri">In PubMed</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&targetsite=external&targetcat=link&targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/masterlistintro/">Master List of LiverTox Drugs [with Metadata]</a></li><li><a href="/books/n/livertox/drugliverinjury/">LiverTox Drugs by Drug Class</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26207888" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> A historical overview of protein kinases and their targeted small molecule inhibitors.</a><span class="source">[Pharmacol Res. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> A historical overview of protein kinases and their targeted small molecule inhibitors.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Roskoski R Jr. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacol Res. 2015 Oct; 100:1-23. Epub 2015 Jul 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18158072" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.</a><span class="source">[Clin Ther. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Steinberg M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ther. 2007 Nov; 29(11):2289-308. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12191602" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.</a><span class="source">[Pharmacol Ther. 2002]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacol Ther. 2002 Feb-Mar; 93(2-3):79-98. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12154026" ref="ordinalpos=1&linkpos=4&log$=relatedarticles&logdbfrom=pubmed">Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.</a><span class="source">[Cancer Res. 2002]</span><div class="brieflinkpop offscreen_noflow">Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cancer Res. 2002 Aug 1; 62(15):4244-55. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12908554" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.</a><span class="source">[Adv Exp Med Biol. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sattler M, Scheijen B, Weisberg E, Griffin JD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Exp Med Biol. 2003; 532:121-40. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=31643906" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=31643906" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c8e137a68b6b5afc7756f5">Protein Kinase Inhibitors - LiverTox</a><div class="ralinkpop offscreen_noflow">Protein Kinase Inhibitors - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c8e135f4a390645e3494aa">Protease Inhibitors (HIV) - LiverTox</a><div class="ralinkpop offscreen_noflow">Protease Inhibitors (HIV) - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c8e134f4a390645e348f83">Protease Inhibitors (HCV) - LiverTox</a><div class="ralinkpop offscreen_noflow">Protease Inhibitors (HCV) - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=67c8e133ab82281a803f6385">Prostacyclin Analogs - LiverTox</a><div class="ralinkpop offscreen_noflow">Prostacyclin Analogs - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=5" href="/portal/utils/pageresolver.fcgi?recordid=67c8e132a68b6b5afc774474">Propylthiouracil - LiverTox</a><div class="ralinkpop offscreen_noflow">Propylthiouracil - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
|
|
|
<!-- Custom content below discovery portlets -->
|
|
<div class="col7">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
<!-- Custom content after all -->
|
|
<div class="col8">
|
|
|
|
</div>
|
|
<div class="col9">
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
|
<script type="text/javascript">
|
|
(function($){
|
|
$('.skiplink').each(function(i, item){
|
|
var href = $($(item).attr('href'));
|
|
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
|
$(item).on('click', function(event){
|
|
event.preventDefault();
|
|
$.scrollTo(href, 0, {
|
|
onAfter: function(){
|
|
href.focus();
|
|
}
|
|
});
|
|
});
|
|
});
|
|
})(jQuery);
|
|
</script>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<div class="footer" id="footer">
|
|
<section class="icon-section">
|
|
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
|
<div class="grid-container container">
|
|
<div class="icon-section_container">
|
|
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11 {
|
|
fill: #737373;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>Twitter</title>
|
|
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>Facebook</title>
|
|
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>LinkedIn</title>
|
|
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11,
|
|
.cls-12 {
|
|
fill: #737373;
|
|
}
|
|
|
|
.cls-11 {
|
|
fill-rule: evenodd;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>GitHub</title>
|
|
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
|
</path>
|
|
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
|
</path>
|
|
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
|
</path>
|
|
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
|
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
|
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
|
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
|
<title>NCBI Insights Blog</title>
|
|
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
|
</svg>
|
|
</a>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
|
|
<section class="container-fluid bg-primary">
|
|
<div class="container pt-5">
|
|
<div class="row mt-3">
|
|
<div class="col-lg-3 col-12">
|
|
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
|
<ul class="list-inline social_media">
|
|
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st20 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st30 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Twitter</title>
|
|
<g>
|
|
<g>
|
|
<g>
|
|
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
|
</g>
|
|
</svg></a></li>
|
|
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
|
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st10 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st110 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Facebook</title>
|
|
<g>
|
|
<g>
|
|
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
|
</svg>
|
|
</a></li>
|
|
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<title>Youtube</title>
|
|
<style type="text/css">
|
|
.st4 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
|
|
.st5 {
|
|
fill: #FFFFFF;
|
|
}
|
|
</style>
|
|
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
|
<g transform="translate(0,-952.36218)">
|
|
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
|
</g>
|
|
</svg></a></li>
|
|
</ul>
|
|
</div>
|
|
<div class="col-lg-3 col-12">
|
|
<p class="address_footer text-white">National Library of Medicine<br />
|
|
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
|
Bethesda, MD 20894</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
|
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
|
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
|
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
|
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-12 centered-lg">
|
|
<nav class="bottom-links">
|
|
<ul class="mt-3">
|
|
<li>
|
|
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
|
</li>
|
|
</ul>
|
|
</nav>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK548591&ncbi_domain=livertox&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK548591/&ncbi_pagename=Protein Kinase Inhibitors - LiverTox - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |